Clinical Trials on Influenza A Virus, H5N1 Subtype in Switzerland

Total 65 results

Novartis Vaccines

Completed

Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine

Novel Influenza A (H1N1) | A New Flu Virus of Swine Origin

Chile, Colombia, Germany, Switzerland
University of Alberta
University of Lausanne Hospitals

Completed

Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients

Influenza Vaccine | Influenza Virus

Switzerland, Canada
Novartis
Novartis Vaccines

Completed

Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine

Influenza Infection

Switzerland
University of Zurich
Schweizerischer Nationalfonds

Completed

Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting (TransFLUas)

Human Influenza

Switzerland
University of Lausanne Hospitals

Completed

Imiquimod and Influenza Vaccine for Immunocompromised Patients (IMIFLU)

Influenza Vaccine

Switzerland
Crucell Holland BV

Completed

Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains

Influenza

Switzerland
Novartis Vaccines

Completed

Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines

Influenza

Switzerland
Crucell Holland BV

Completed

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains

Influenza

Switzerland
Crucell Holland BV

Completed

A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern Hemisphere

Influenza

Switzerland
Crucell Holland BV

Completed

A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern Hemisphere

Influenza

Switzerland
Crucell Holland BV

Completed

Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers

Influenza

Switzerland
Crucell Holland BV

Completed

A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere

Influenza

Switzerland
University Hospital, Basel, Switzerland
University of Basel; Swiss Federal Institute of Technology; University Children...

Completed

Prospective Analysis of Seasonal Influenza - Viral Transmission and Evolution in the City of Basel, Switzerland

Influenza

Switzerland
Crucell Holland BV

Completed

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)

Influenza

Switzerland
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation

Influenza

Switzerland
Crucell Holland BV

Completed

Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers

Influenza

Switzerland
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
University of Lausanne Hospitals

Completed

Rapid Flu Tests in Travelers With Fever

Influenza

Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine

Influenza | Orthomyxoviridae Infections

Switzerland, United Kingdom
University Hospital Inselspital, Berne
Merck Sharp & Dohme LLC; Boehringer Ingelheim; Abbott; Solvay Pharmaceuticals

Completed

Influenza Vaccination in Immunocompromized Patients

Immunosuppression

Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity Study of the Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infections

Belgium, Germany, Switzerland
Johannes Scherr

Recruiting

GRIP: Maximum Isometric Grip Strength Assessed With Three Different Hand-held Dynamometers

Grip

Switzerland
Oriol Manuel
University of Zurich; University Hospital, Geneva; University Hospital, Basel... and other collaborators

Completed

Reducing the Burden of Influenza After Solid-Organ Transplantation (STOP-FLU)

Influenza | Organ Transplantation

Switzerland, Spain
University of Lausanne Hospitals

Completed

What is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years (AHAV)

Hepatitis A

Switzerland
Ente Ospedaliero Cantonale, Bellinzona
Clinical Trial Unit Ente Ospedaliero Cantonale; Swiss Transfusion SRC

Completed

Seroprevalence Hepatitis E Infection in Healthy Blood Donors

Hepatitis E

Switzerland
University Hospital, Basel, Switzerland

Terminated

Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine (SASL28)

Hepatitis, Chronic

Switzerland
University Hospital, Geneva
ModernaTX, Inc.; University of Geneva, Switzerland

Active, not recruiting

Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study (MIViral)

SARS-CoV-2 Infection | RSV Infection | Influenza Viral Infections | Virus Shedding | Mucosal Immunity

Switzerland
University of Zurich
PD Dr. rer. nat. Mathias Heikenwälder

Unknown

A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.

Chronic HCV Hepatitis C

Switzerland
Bristol-Myers Squibb
Basel Institute of Clinical Epidemiology (BICE)

Completed

Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period

Hepatitis C

Switzerland
Pevion Biotech Ltd

Completed

Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides

Chronic Hepatitis C

Switzerland
University Hospital, Basel, Switzerland

Completed

Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine

Hepatitis C

Switzerland
Patricia Schlagenhauf
University Hospital, Geneva; Swiss Tropical & Public Health Institute; ETH Zurich and other collaborators

Not yet recruiting

Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria (ITIT)

Diarrhea | Malaria | Influenza | SARS-CoV Infection | Dengue | Chikungunya | Zika | Travel-Related Illness | MERS

Switzerland
Hoffmann-La Roche

Completed

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

Influenza, Human

United States, Spain, Belgium, Poland, Germany, United Kingdom, Chile, Estonia, Hungary, Italy, France, South Africa, Mexico, Israel, Brazil, Guatemala, Czechia, Lithuania, Argentina, Bulgaria, Canada, Colombia, Latvia, Romania, Switzer... and more
Kantonsspital Olten

Completed

Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection

Pulmonary Artery Hypertension | Chronic Hepatitis c

Switzerland
University Hospital, Geneva

Completed

Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone

Chronic Hepatitis C

Switzerland
Novartis Pharmaceuticals

Terminated

Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus

Hepatitis C | Liver Transplant

United States, Switzerland
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

Hepatitis C Virus Infection

Spain, Switzerland, United Kingdom
GlaxoSmithKline

Completed

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

Hepatitis B

Australia, Czech Republic, Germany, Italy, Netherlands, Switzerland, United Kingdom
University of Bern
Roche Pharma AG; University of Lausanne; University of Basel; Cantonal Hospital... and other collaborators

Completed

High Dose Ribavirin in the Treatment of Chronic Hepatitis C

Chronic Hepatitis C

Switzerland
Fondazione Epatocentro Ticino

Recruiting

Swiss Autoimmune Hepatitis Cohort Study

Hepatitis, Autoimmune

Switzerland
AbbVie

Completed

Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®) (HEMATITE)

Chronic Hepatitis C Virus (HCV)

Switzerland
Janssen Pharmaceutica N.V., Belgium

Completed

Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C (INTEGRATE)

Hepatitis, Chronic

France, United Kingdom, Belgium, Germany, Netherlands, Switzerland
Novartis Pharmaceuticals

Active, not recruiting

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (AMBER)

Autoimmune Hepatitis

United States, Belgium, Germany, United Kingdom, Spain, Switzerland, Argentina, Canada, Japan, Czechia
Kirby Institute

Completed

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients (SMART-C)

Hepatitis C, Chronic

United States, United Kingdom, Australia, France, New Zealand, Canada, Switzerland, Germany
Novartis Pharmaceuticals

Completed

Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C (SUSTAIN)

Liver Transplantation | Hepatitis C

Spain, Germany, Switzerland, Italy, United States, Korea, Republic of, Canada, Colombia, Belgium, Brazil, France, United Kingdom, Russian Federation
AbbVie

Completed

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (MAGELLAN-3)

Hepatitis C Virus Infection

United States, Australia, Canada, China, Germany, Korea, Republic of, New Zealand, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)

Hepatitis C

Austria, Belgium, France, Germany, Japan, Portugal, Romania, Russian Federation, Spain, Switzerland, United Kingdom
Hoffmann-La Roche

Completed

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Chronic Hepatitis B

China, Korea, Republic of, Taiwan, Germany, United States, Singapore, Switzerland, Canada, Puerto Rico, Thailand, Israel, France, New Zealand, Poland, United Kingdom, Brazil, Australia
Boehringer Ingelheim

Completed

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Hepatitis C

United States, Austria, Belgium, Canada, France, Germany, Japan, Korea, Republic of, Portugal, Romania, Russian Federation, Spain, Switzerland, Taiwan, United Kingdom

Clinical Trials on Influenza A Virus, H5N1 Subtype in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations